193 related articles for article (PubMed ID: 28558972)
21. Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action.
Wexler-Cohen Y; Shai Y
PLoS Pathog; 2009 Jul; 5(7):e1000509. PubMed ID: 19593361
[TBL] [Abstract][Full Text] [Related]
22. A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity.
Su S; Wang Q; Xu W; Yu F; Hua C; Zhu Y; Jiang S; Lu L
AIDS; 2017 Apr; 31(7):885-894. PubMed ID: 28121713
[TBL] [Abstract][Full Text] [Related]
23. The C34 Peptide Fusion Inhibitor Binds to the Six-Helix Bundle Core Domain of HIV-1 gp41 by Displacement of the C-Terminal Helical Repeat Region.
Louis JM; Baber JL; Clore GM
Biochemistry; 2015 Nov; 54(45):6796-805. PubMed ID: 26506247
[TBL] [Abstract][Full Text] [Related]
24. Identification of Ebola Virus Inhibitors Targeting GP2 Using Principles of Molecular Mimicry.
Singleton CD; Humby MS; Yi HA; Rizzo RC; Jacobs A
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092576
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
Pan C; Liu S; Jiang S
J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
[TBL] [Abstract][Full Text] [Related]
26. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
Li W; Lu L; Li W; Jiang S
Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
[TBL] [Abstract][Full Text] [Related]
27. Stabilizing the native trimer of HIV-1 Env by destabilizing the heterodimeric interface of the gp41 postfusion six-helix bundle.
Kesavardhana S; Varadarajan R
J Virol; 2014 Sep; 88(17):9590-604. PubMed ID: 24920800
[TBL] [Abstract][Full Text] [Related]
28. Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.
Zhuang M; Wang W; De Feo CJ; Vassell R; Weiss CD
J Biol Chem; 2012 Mar; 287(11):8297-309. PubMed ID: 22235115
[TBL] [Abstract][Full Text] [Related]
29. The M-T hook structure is critical for design of HIV-1 fusion inhibitors.
Chong H; Yao X; Sun J; Qiu Z; Zhang M; Waltersperger S; Wang M; Cui S; He Y
J Biol Chem; 2012 Oct; 287(41):34558-68. PubMed ID: 22879603
[TBL] [Abstract][Full Text] [Related]
30. Origins of resistance to the HIVgp41 viral entry inhibitor T20.
McGillick BE; Balius TE; Mukherjee S; Rizzo RC
Biochemistry; 2010 May; 49(17):3575-92. PubMed ID: 20230061
[TBL] [Abstract][Full Text] [Related]
31. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques.
Liu S; Jiang S
Curr Pharm Des; 2004; 10(15):1827-43. PubMed ID: 15180543
[TBL] [Abstract][Full Text] [Related]
32. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides.
Liu S; Jing W; Cheung B; Lu H; Sun J; Yan X; Niu J; Farmar J; Wu S; Jiang S
J Biol Chem; 2007 Mar; 282(13):9612-9620. PubMed ID: 17276993
[TBL] [Abstract][Full Text] [Related]
33. Addition of artificial salt bridge by Ile646Lys mutation in gp41 coiled-coil domain regulates 6-helical bundle formation.
Zhao L; Hu ZW; Tong P; Chen YX; Zhao YF; Li YM
Bioorg Med Chem Lett; 2013 May; 23(9):2727-32. PubMed ID: 23522564
[TBL] [Abstract][Full Text] [Related]
34. The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for viral fusion and entry.
Wang X; Xiong W; Ma X; Wei M; Chen Y; Lu L; Debnath AK; Jiang S; Pan C
PLoS One; 2012; 7(9):e44874. PubMed ID: 22970321
[TBL] [Abstract][Full Text] [Related]
35. Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.
Geng X; Liu Z; Yu D; Qin B; Zhu Y; Cui S; Chong H; He Y
Viruses; 2019 Jul; 11(7):. PubMed ID: 31277353
[TBL] [Abstract][Full Text] [Related]
36. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
[TBL] [Abstract][Full Text] [Related]
37. Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics.
De Feo CJ; Wang W; Hsieh ML; Zhuang M; Vassell R; Weiss CD
Retrovirology; 2014 Oct; 11():86. PubMed ID: 25274545
[TBL] [Abstract][Full Text] [Related]
38. Anti-HIV-1 Activity Prediction of Novel Gp41 Inhibitors Using Structure-Based Virtual Screening and Molecular Dynamics Simulation.
Sepehri S; Saghaie L; Fassihi A
Mol Inform; 2017 Mar; 36(3):. PubMed ID: 27730744
[TBL] [Abstract][Full Text] [Related]
39. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
[TBL] [Abstract][Full Text] [Related]
40. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.
Zhao L; Tong P; Chen YX; Hu ZW; Wang K; Zhang YN; Zhao DS; Cai LF; Liu KL; Zhao YF; Li YM
Org Biomol Chem; 2012 Aug; 10(32):6512-20. PubMed ID: 22760295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
